Denosumab Therapy Guidelines

Primary Indications for Denosumab

The European Society for Medical Oncology recommends initiating denosumab 120 mg subcutaneously every 4 weeks in all patients with bone metastases from solid tumors, regardless of symptoms, after ensuring adequate calcium/vitamin D supplementation and dental evaluation 1, 2
The American Society of Clinical Oncology suggests starting denosumab immediately upon diagnosis of bone metastases in metastatic breast cancer patients, whether symptomatic or asymptomatic 1
The National Comprehensive Cancer Network recommends initiating denosumab in all patients with bone metastases from castration-resistant prostate cancer, regardless of symptoms 1
The European Society for Medical Oncology recommends using denosumab in selected patients with life expectancy >3 months who are at high risk of skeletal-related events (SREs) from other solid tumors (lung, renal, etc.) 1

The American Society of Clinical Oncology recommends a dosing regimen of 120 mg subcutaneously every 4 weeks for bone metastases, without extending intervals beyond 4 weeks 2
The British Journal of Cancer suggests a dosing regimen of three loading doses at weekly intervals, then monthly, for giant cell tumor of bone 4
The American Society of Clinical Oncology recommends a dosing regimen of 60 mg subcutaneously every 6 months for cancer treatment-induced bone loss 3

The European Society for Medical Oncology recommends completing a dental evaluation before initiating denosumab to minimize osteonecrosis of the jaw (ONJ) risk 1, 2
The American Society of Clinical Oncology suggests initiating calcium and vitamin D supplementation before starting denosumab, with a recommended daily dose of 1,200-1,500 mg calcium and 400-800 IU vitamin D3 3

The American Society of Clinical Oncology recommends continuing denosumab without planned interruption as long as bone disease requires treatment 3
The British Journal of Cancer suggests extending intervals from 4-weekly to 8-weekly for stable disease after 2 years in giant cell tumor of bone 4
The American Society of Clinical Oncology recommends continuing denosumab throughout aromatase inhibitor or androgen deprivation therapy, typically up to 2 years, for cancer treatment-induced bone loss 3

The European Society for Medical Oncology warns that denosumab should not be stopped abruptly, and bisphosphonate therapy should be initiated to prevent rebound bone loss and multiple vertebral fractures if denosumab is discontinued 3
The American Society of Clinical Oncology recommends monitoring for key adverse events, including hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, and serious infections 1, 2